Abstract:Type 1 diabetes mellitus (T1DM) is a chronic immunemediated disease that specifically targets insulin-producing pancreatic b cells. Atopic dermatitis (AD) or eczema is a polyfactorial chronic relapsing inflammatory/autoimmune disease with a major impact on quality of life that has been often associated with other comorbidities. Both diseases have a mainly childhood onset. However, although both diseases are considered to be immune-mediated, AD is driven by T-helper (Th) 2-dependent inflammation, whereas T1DM is mediated mainly by a Th1 response; these two pathways being theoretically mutually inhibitory. In this issue of the BJD, Lin et al. propose a populationbased, retrospective cohort study, the main aim of which was to analyse the association between T1DM and AD using claims data from the National Health Insurance program of Taiwan. They identified 3386 patients with T1DM newly diagnosed from 1998 to 2011 and 12 725 randomly selected controls without T1DM. The 12 725 controls were matched by age, sex and year of diagnosis. All patients were followed up until the end of 2011 and AD was notified if it developed. Both cohorts were compared using Cox proportional hazards regression models to analyse the risk of AD. The main result of this study is that the overall incidence rate of AD was significantly higher in the T1DM cohort than in the non-T1DM cohort even after adjustment for potential risk factors. However, the AD incidence densities were shown to be very low in both groups (fewer than three new patients with AD per 1000 patient-years). This finding may be due to the high mean age (11 years) of the children in both cohorts. Indeed, most patients with AD have usually been diagnosed before this age. In addition, the authors showed that among patients with T1DM, only those with more emergency room visits or hospitalizations had a higher risk of subsequent AD compared with the non-T1DM cohort. This latter finding may raise the possibility of a surveillance bias in the T1DM cohort, as children with more hospitalizations undergo more clinical followup. In the past, the association of AD and T1DM has drawn conflicting results and to date no other study has found a significant association between these two diseases. Although the validity of the results may be restricted to Chinese ethnic groups, the strength of the study by Lin et al. is that this is the first nationwide study that has been performed to examine this association. The apparent and oversimplified antagonism between these two diseases, i.e. AD is driven by Th2-dependent inflammation whereas T1DM is mediated mainly by a Th1 response, may reflect the complexity of deciphering the immune pathways in autoimmune/autoinflammatory diseases. Moreover, it is probable that different endophenotypes exist within the spectrum of AD and T1DM, which may have different immune pathways and add to the complexity of the pathophysiological picture underlying these diseases. Further prospective studies taking into account the different endophenotypes/stages of both diseases and more potential confounding factors are thus needed to confirm this association.

Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study

Malignancy risk in patients with atopic dermatitis: a population-based cohort study

Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits

Ultraviolet B phototherapy does not increase the risk of skin cancer among patients with atopic dermatitis: A population-based retrospective cohort study

Association of Countries' Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization

Intermittent or Sequential Topical Tacrolimus in Atopic Dermatitis: Systematic Review and Meta-Analysis

Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study

Prescription Patterns of Topical Medications in Patients with Atopic Dermatitis: An Investigative Review Using Big Data from the National Health Insurance Corporation

Carcinogenicity risk associated with tacrolimus use in kidney transplant recipients: a systematic review and meta-analysis

Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: Will immunosuppressants work?

Effect of mammalian-target-of-rapamycin inhibitors on the cancer risk in patients receiving calcineurin inhibitors: Data mining of a spontaneous reporting database

Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study

Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study

Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach

Basal Cell Carcinoma in Organ Transplant Recipients

Hydrochlorothiazide Use and Risk of Skin Cancer: A Population‐Based Retrospective Cohort Study

Association Between Antihypertensive Medications and Risk of Skin Cancer in People Older Than 65 Years: a Population-Based Study.

Association between cancer and immunosuppressive therapy--analysis of selected studies in pemphigus and pemphigoid

Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database

Tetracycline Use and Risk of Incident Skin Cancer: a Prospective Study

RISK OF MALIGNANCY WITH NON-TNFI BIOLOGIC OR TOFACITINIB THERAPY IN RHEUMATOID ARTHRITIS: A META-ANALYSIS OF OBSERVATIONAL STUDIES